Bladder cancer company Photocure ASA (OSE: PHO) announced on Monday that its partner Asieris Pharmaceuticals (SSE: 688176) presented subgroup data from its Phase III clinical trial for Cevira (APL-1702) at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting.

This trial, focused on the non-surgical treatment of cervical High-Grade Squamous Intraepithelial Lesion (HSIL), demonstrated significant pathological regression and HPV clearance rates, especially in patients aged 20 to 40.

The randomised, double-blind, placebo-controlled trial showed a 15-20% increase in pathological regression in key age groups and strong HPV clearance in younger patients. The drug-device combination offers promise as a non-invasive HSIL treatment, with further validation needed for younger and older age groups.

Cevira achieved its primary efficacy endpoint in 2023, with an NDA accepted by China's NMPA in May 2024.